Neuronetics Employee Patient Advocates Honor Mental Health Awareness Month by Sharing Personal Depression Experiences
May 03 2021 - 8:00AM
Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical
technology company focused on designing, developing and marketing
products that improve the quality of life for patients who suffer
from psychiatric disorders, is honoring the depression journeys of
its employees and all those who suffer from depression in
observance of Mental Health Awareness Month.
Depression is a disease that does not discriminate and currently
impacts more than 17.3 million American adults1, with rates rapidly
rising as a result of the COVID-19 pandemic. New research shows as
many as 1 in 3 COVID-19 survivors suffer from neurological or
mental disorders, with 13 percent of patients diagnosed for the
first time, most often with depression or anxiety2. As the mental
health pandemic continues to gain momentum, Neurostar employees are
working more passionately than ever to encourage open and honest
conversation about mental health and educate the community about
NeuroStar Advanced Therapy for Mental Health, a proven, non-drug,
non-invasive treatment for adults with Major Depressive Disorder
(MDD). These employees have personally undergone NeuroStar
treatments and are using their experiences to help educate
individuals in their communities who need it now more than
ever.
“Mental Health Awareness Month is especially poignant this year
as we continue to address the emotional toll of a global pandemic,”
said Keith J. Sullivan, President and CEO of Neuronetics. “We are
proud to showcase the devotion of our employees who believe so
deeply in this Company and in NeuroStar Advanced Therapy, because
they’ve seen for themselves the impact it can have. Our patients
are also our people, and we applaud their desire to openly share
their raw experiences in hope of inspiring others to seek the help
they need and deserve.”
Several employees are leading the charge, drawing upon their own
NeuroStar treatment journeys to educate both providers and
patients. Bridget, Eric and Cara are employee patient advocates
striving to build awareness:
- Bridget is a NeuroStar Practice Consultant-turned-patient
advocate whose depression began when she was a teenager and
persisted into adulthood. During the height of the pandemic, a year
after she began working at NeuroStar, her depression worsened, and
she made the decision to try NeuroStar Advanced Therapy for
herself.“I am a perfect example of what an invisible struggle
depression can be. So many of my colleagues were surprised to hear
of my depression because I was highly functional and seemingly had
it all together,” said Bridget. “Deep down I was in a constant
mental fog and dreaded getting up each morning. After treatment, I
am motivated and eager to start my days. I’m living proof for the
patients I work with that NeuroStar can change lives – it changed
my life and the life of my entire family.”
- Eric is a NeuroStar patient from Los Angeles, CA so motivated
by his experience that he sought out an opportunity to work as a
Practice Consultant for the Company he credits with changing his
life. After 2010 surgical complications left Eric on life support,
he struggled to recover for years, ultimately falling into a deep
depression. When antidepressants failed, he was referred to
NeuroStar Advanced Therapy and began treatment a few years
ago.“About two weeks into my treatment, something clicked. I felt
motivated again. I walked out of my appointment and said to myself
‘I’m going to work for this company someday,’” said Eric.
“NeuroStar gave me the relief I needed to become a better father,
sibling and co-parent. Being a true believer has made me better at
my job and allowed me to more empathetically expand mental health
awareness as I educate practices and patients.”
- Cara, a NeuroStar Clinical Training Consultant from Texas, is
another patient-turned-employee who suffered from treatment
resistant depression for almost twenty years. After unsuccessful
trials with countless antidepressants, Cara found relief from her
symptoms through NeuroStar Advanced Therapy. Her energy and
motivation soon returned, and her passion for the treatment led her
to pursue a career at NeuroStar.“I’m able to relate to patients on
a whole new level, because I’ve been in their shoes,” said Cara. “I
think we all carry a backpack around with us each day – we all have
our own personal loads to carry, but those of us with depression
have heavy bricks in our bags. Thanks to NeuroStar, the bricks in
my bag are gone, and my hope is I can help others understand that
the same outcome is possible for them.”
These personal journeys showcase how far-reaching depression can
be, and how motivated those who have overcome the disease are to
tell their stories in the hope of supporting others. Neuronetics
remains dedicated this month and every month to encouraging
powerful conversations, educating patients and providers, and
celebrating the brave faces of Neuronetics employees who
passionately live the Company’s mission each day.
More than 3.5 million NeuroStar treatments have been delivered
across nearly 1,000 practice locations in the U.S., and the
NeuroStar footprint continues to expand. To join the conversation
during Mental Health Month, follow NeuroStar on LinkedIn, Facebook,
Instagram, and Twitter, and access additional resources on
YouTube. For more information about NeuroStar Advanced Therapy,
visit www.neurostar.com.
About NeuroneticsNeuronetics, Inc. is a
commercial-stage medical technology company focused on designing,
developing, and marketing products that improve the quality of life
for patients who suffer from psychiatric disorders. Its commercial
product, the NeuroStar® Advanced Therapy System, is a non-invasive
and non-systemic office-based treatment that uses transcranial
magnetic stimulation, or TMS, to create a pulsed, MRI-strength
magnetic field that induces electrical currents designed to
stimulate specific areas of the brain associated with mood. The
system is cleared by the United States Food and Drug
Administration, or FDA, for the treatment of major depressive
disorder in adult patients who have failed to achieve satisfactory
improvement from prior antidepressant medication in the current
episode. Visit NeuroStar.com for safety information and indications
for use. NeuroStar is also available in other parts of the world,
including Japan, where it is listed under Japan’s national
health insurance. Additional information can be found
at www.neuronetics.com.
Media Contact:Chelsey MankoVault
Communications610-455-2778cmanko@vaultcommunications.com ________________________________
1 https://www.nimh.nih.gov/health/statistics/major-depression.shtml,
accessed 3/24/212
https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(21)00084-5/fulltext,
accessed 4/11/21
Neuronetics (NASDAQ:STIM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Neuronetics (NASDAQ:STIM)
Historical Stock Chart
From Sep 2023 to Sep 2024